Zacks: Analysts Expect Baxter International Inc (BAX) Will Announce Earnings of $0.60 Per Share

Equities research analysts expect Baxter International Inc (NYSE:BAX) to announce earnings of $0.60 per share for the current quarter, according to Zacks. Six analysts have made estimates for Baxter International’s earnings. The lowest EPS estimate is $0.48 and the highest is $0.63. Baxter International posted earnings per share of $0.58 during the same quarter last year, which would suggest a positive year-over-year growth rate of 3.4%. The company is scheduled to announce its next earnings report on Wednesday, April 25th.

On average, analysts expect that Baxter International will report full-year earnings of $2.74 per share for the current financial year, with EPS estimates ranging from $2.33 to $2.80. For the next financial year, analysts anticipate that the firm will report earnings of $3.09 per share, with EPS estimates ranging from $2.70 to $3.20. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Baxter International.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.05. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.77 billion. Baxter International had a net margin of 6.79% and a return on equity of 15.12%. Baxter International’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the company posted $0.57 earnings per share.

Several equities analysts recently weighed in on BAX shares. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a research note on Tuesday, October 24th. Bank of America upgraded shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. BMO Capital Markets reiterated a “buy” rating and set a $70.00 price objective on shares of Baxter International in a research report on Friday, October 13th. Morgan Stanley increased their price objective on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $66.00 price objective on shares of Baxter International in a research report on Wednesday, November 22nd. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Baxter International currently has an average rating of “Buy” and an average price target of $70.36.

Baxter International (NYSE BAX) traded up $1.75 on Friday, reaching $64.31. 5,680,000 shares of the company traded hands, compared to its average volume of 3,340,000. The stock has a market capitalization of $36,020.00, a PE ratio of 49.47, a price-to-earnings-growth ratio of 1.77 and a beta of 0.78. Baxter International has a 52 week low of $48.58 and a 52 week high of $72.58. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37.

In other news, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the sale, the senior vice president now owns 124,609 shares in the company, valued at approximately $8,130,737.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Family Capital Trust Co bought a new stake in shares of Baxter International in the 4th quarter worth about $103,000. Community Bank N.A. lifted its holdings in shares of Baxter International by 152.7% in the 4th quarter. Community Bank N.A. now owns 1,655 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 1,000 shares during the last quarter. Trustcore Financial Services LLC bought a new stake in shares of Baxter International in the 4th quarter worth about $131,000. Grove Bank & Trust lifted its holdings in shares of Baxter International by 526.0% in the 3rd quarter. Grove Bank & Trust now owns 2,285 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,920 shares during the last quarter. Finally, Cerebellum GP LLC bought a new stake in shares of Baxter International in the 4th quarter worth about $173,000. Hedge funds and other institutional investors own 83.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Baxter International Inc (BAX) Will Announce Earnings of $0.60 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/10/zacks-analysts-expect-baxter-international-inc-bax-will-announce-earnings-of-0-60-per-share.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Get a free copy of the Zacks research report on Baxter International (BAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply